Clinical Microbiology and Antimicrobial Chemotherapy. 2001; 3(3):243-259
Moxifloxacin – new broad spectrum 8-methoxyquinolon with high activity against Gram(+) and Gram(-) microorganisms as well as against anaerobes and intracellular pathogens. It is also active against microorganisms that are resistant to other classes of antimicrobials, including penicillin- and macrolide-resistant pneumococci and b-lactamase-producing Haemophilus influenzae. In the controlled clinical trials the high clinical efficacy and safety of moxifloxacin have been demonstrated for community-acquired pneumonia, exacerbation of chronic bronchitis, acute sinusitis, skin and soft tissue infections, pelvic inflammatory diseases. In the article the literature review of microbiological studies and clinical trials on moxifloxacin is presented.